ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 89 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,788 | -96.4% | 10,789 | -94.4% | 0.00% | -100.0% |
| Q2 2023 | $1,452,997 | -7.3% | 193,475 | -44.2% | 0.00% | 0.0% |
| Q1 2023 | $1,567,487 | -59.4% | 346,789 | +1.3% | 0.00% | -50.0% |
| Q4 2022 | $3,858,341 | +17.8% | 342,355 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,275,000 | +18.4% | 342,213 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $2,765,000 | -52.4% | 341,819 | -0.5% | 0.00% | -33.3% |
| Q1 2022 | $5,807,000 | +2270.2% | 343,663 | +2909.3% | 0.00% | – |
| Q4 2021 | $245,000 | -78.8% | 11,420 | -26.9% | 0.00% | -100.0% |
| Q3 2021 | $1,153,000 | +87.2% | 15,623 | +38.7% | 0.00% | – |
| Q2 2021 | $616,000 | -28.0% | 11,263 | -3.0% | 0.00% | – |
| Q1 2021 | $855,000 | +39.0% | 11,608 | +62.8% | 0.00% | – |
| Q4 2020 | $615,000 | +218.7% | 7,132 | +39.6% | 0.00% | – |
| Q3 2020 | $193,000 | – | 5,108 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |